Amyloid Beta-Peptide (12-28) (human) |
| Katalog-Nr.GP10049 |
Amyloid Beta-Peptide (12-28) (human) is a peptide fragment of amyloid beta protein (1-42) (Aβ (1-42)).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 107015-83-8
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Amyloid Beta-Peptide (12-28) (human) is a peptide fragment of amyloid beta protein (1-42) (Aβ (1-42)) [1]. One of the neuropathological features of Alzheimer's disease (AD) is the presence of amyloid deposits in senile plaques and in blood vessel walls [2]. Amyloid Beta-Peptide (12-28) was used as an internal standard [1].
Amyloid Beta-Peptide (12-28) (human) could efficiently suppress the formation of the α7nAChR.Aβ (1-42) complex. Using human brain tissues and cells that overexpress either the α7 nicotinic acetylcholine receptor (α7nAChR) or amyloid precursor protein as the starting material, Aβ (1-42) and α7nAChR can be co-immunoprecipitated by the respective specific antibodies, suggesting that they are tightly associated [3].
References:
[1]. Wang R, Sweeney D, Gandy SE, Sisodia, SS (1996) The profile of soluble amyloid b protein in cultured cell media. Detection and quantificaiton of amyloid β protein and variants by immunoprecipitation-mass spectrometry. J Biol Chem 271:31894-31902.
[2]. Terry R. D., and Davies P.(1983) Aging of the Brain (Samuel, D., Algeri, S.,Gershon ,S., Grimm, V., and Toffano, G., eds) Vol. 22, pp. 47-59, Raven Press
[3]. Wang, H. Y. et al. β-Amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 275, 5626-5632 (2000).
| Cell experiment [1]: | |
|
Cell lines |
PC12 cells |
|
Preparation Method |
Two days after plating cell were treated with different concentrations of aged β12-28 peptide. After 22 h, MTT (5 mg/ml) was added and incubation was continued for a further2 h. Cells were lysed and after 24 h at 37°C, colorimetric determination of MTT reduction was made at 550 nm. |
|
Reaction Conditions |
0.001, 0.1, 10, 40 µM for 22 hours |
|
Applications |
Freshly pre-pared solutions of β12 - 28 were non-toxic as expected, while aged solutions produce generally significant decreases in the MTT mitochondrial reduction by PC12 cells. |
|
References: [1]: Rabanal, F., Tusell, J. M., Sastre, L., et al. (2002) Structural, kinetic and cytotox-icity aspects of 12-28 β amyloid protein fragment: A reappraisal. J. Pept. Sci. 8,578-588. |
|
| Cas No. | 107015-83-8 | SDF | |
| Formula | C89H135N25O25 | M.Wt | 1955.2 |
| Löslichkeit | ≥195.5mg/mL in DMSO | Storage | Desiccate at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5115 mL | 2.5573 mL | 5.1146 mL |
| 5 mM | 0.1023 mL | 0.5115 mL | 1.0229 mL |
| 10 mM | 0.0511 mL | 0.2557 mL | 0.5115 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *